STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #610 by analyst upside · 2026-06-27
EPRX
Eupraxia Pharmaceuticals Inc.
Healthcare · Market Cap $431M · P/E 0x
ANALYST PRICE TARGET
+146.6%
implied upside to consensus target
Current Price $6.6
Consensus Target $16.28
Bull Target $25.0
Bear Target $11.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
9
Hold
0
Sell
0
52-Week Low $4.67
52-Week High $9.32
YTD Return -12.8%
FUNDAMENTALS
Market Cap $431M
P/E Ratio (TTM) N/A
Forward P/E -7.3x
EPS (TTM) $-1.05
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.67
52-Week High $9.32
Current Price $6.6
Bear Target $11.0
Bull Target $25.0
● Now $6.6 ● Target $16.28
TRADING DATA
Avg Volume 262K
YTD Return -12.8%
Analyst Count 9
Consensus Buy
Upside to Target +146.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Eupraxia Pharmaceuticals Inc. (EPRX) is currently trading at $6.6 with a Wall Street consensus price target of $16.28, implying potential upside of 146.6% over the next 12 months. 9 analysts currently cover EPRX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $25.0, while the most cautious has a target of $11.0.

EPRX operates in the Healthcare sector with a market capitalisation of $431M. The stock is down 12.8% year-to-date and is currently trading near the lower end of its 52-week range of $4.67 – $9.32.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for EPRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Stifel ● Initiated
Buy 2026-05-21 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-05-04 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-04-22 31% win rate (48 calls)
William Blair ● Initiated
Outperform 2026-03-23 44% win rate (9 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-17 31% win rate (48 calls)
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-01-15 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-01-09 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-08-20 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →